Literature DB >> 28916902

Time for standardization of SBRT planning through large scale clinical data and guideline-based approaches.

Christos Moustakis1,2, Oliver Blanck3,4, Fatemeh Ebrahimi5,6, Mark Ka Heng Chan3, Iris Ernst7, Thomas Krieger8, Marciana-Nona Duma9, Markus Oechsner9, Ute Ganswindt10, Christian Heinz10, Horst Alheit11, Hilbert Blank11, Ursula Nestle12, Rolf Wiehle12, Christine Kornhuber13, Christian Ostheimer13, Cordula Petersen14, Gerhard Pollul15, Wolfgang Baus16, Georg Altenstein16, Eric Beckers17, Katrin Jurianz17, Florian Sterzing18, Matthias Kretschmer19, Heinrich Seegenschmiedt20, Torsten Maass20, Stefan Droege21, Ulrich Wolf22, Juergen Schoeffler23, Uwe Haverkamp5,7, Hans Eich5,7, Matthias Guckenberger24.   

Abstract

Mesh：

Year:  2017        PMID： 28916902     DOI： 10.1007/s00066-017-1216-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

1.  ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer.

Authors:  Matthias Guckenberger; Nicolaus Andratschke; Karin Dieckmann; Mischa S Hoogeman; Morten Hoyer; Coen Hurkmans; Stephanie Tanadini-Lang; Eric Lartigau; Alejandra Méndez Romero; Suresh Senan; Dirk Verellen
Journal:  Radiother Oncol       Date:  2017-07-04       Impact factor: 6.280

2.  Lung stereotactic ablative body radiotherapy: A large scale multi-institutional planning comparison for interpreting results of multi-institutional studies.

Authors:  Francesca Romana Giglioli; Lidia Strigari; Riccardo Ragona; Giuseppina R Borzì; Elisabetta Cagni; Claudia Carbonini; Stefania Clemente; Rita Consorti; Randa El Gawhary; Marco Esposito; Maria Daniela Falco; David Fedele; Christian Fiandra; Maria Cristina Frassanito; Valeria Landoni; Gianfranco Loi; Elena Lorenzini; Maria Rosa Malisan; Carmelo Marino; Enrico Menghi; Barbara Nardiello; Roberta Nigro; Caterina Oliviero; Gabriella Pastore; Mariagrazia Quattrocchi; Ruggero Ruggieri; Irene Redaelli; Giacomo Reggiori; Serenella Russo; Elena Villaggi; Marta Casati; Pietro Mancosu
Journal:  Phys Med       Date:  2016-04-06       Impact factor: 2.685

3.  Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Authors:  Matthias Guckenberger; Rainer J Klement; Michael Allgäuer; Nicolaus Andratschke; Oliver Blanck; Judit Boda-Heggemann; Karin Dieckmann; Marciana Duma; Iris Ernst; Ute Ganswindt; Peter Hass; Christoph Henkenberens; Richard Holy; Detlef Imhoff; Henning K Kahl; Robert Krempien; Fabian Lohaus; Ursula Nestle; Meinhard Nevinny-Stickel; Cordula Petersen; Sabine Semrau; Jan Streblow; Thomas G Wendt; Andrea Wittig; Michael Flentje; Florian Sterzing
Journal:  Radiother Oncol       Date:  2015-09-15       Impact factor: 6.280

4.  Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy.

Authors:  Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi Tazehmahalleh; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Theodor Eich; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2017-05-31       Impact factor: 3.621

5.  Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.

Authors:  Lina Zhao; Shouhao Zhou; Peter Balter; Chan Shen; Daniel R Gomez; James D Welsh; Steve H Lin; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-18       Impact factor: 7.038

6.  Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.

Authors:  Matthias Guckenberger; Michael Allgäuer; Steffen Appold; Karin Dieckmann; Iris Ernst; Ute Ganswindt; Richard Holy; Ursula Nestle; Meinhard Nevinny-Stickel; Sabine Semrau; Florian Sterzing; Andrea Wittig; Nicolaus Andratschke
Journal:  J Thorac Oncol       Date:  2013-08       Impact factor: 15.609

7.  Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer.

Authors:  M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621

8.  Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.

Authors:  Norio Katoh; Itaru Soda; Hiroyasu Tamamura; Shotaro Takahashi; Yusuke Uchinami; Hiromichi Ishiyama; Kiyotaka Ota; Tetsuya Inoue; Rikiya Onimaru; Keiko Shibuya; Kazushige Hayakawa; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2017-01-05       Impact factor: 3.481

9.  GTV-based prescription in SBRT for lung lesions using advanced dose calculation algorithms.

Authors:  Thomas Lacornerie; Albert Lisbona; Xavier Mirabel; Eric Lartigau; Nick Reynaert
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481
  9 in total
  1 in total

Review 1.  ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams : Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery.

Authors:  Lotte Wilke; Nicolaus Andratschke; Oliver Blanck; Thomas B Brunner; Stephanie E Combs; Anca-Ligia Grosu; Christos Moustakis; Daniela Schmitt; Wolfgang W Baus; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2019-01-16       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.